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Background: Asthma exacerbations are common during pregnancy with a prevalence as high as
51.9% among women with severe asthma.
Objective: To compare the treatment of asthma exacerbations in an acute-care setting during
and outside of pregnancy.
Methods: We formed a cohort of women who sought medical care for an asthma exacerbation
at a teaching hospital during or in the year preceding pregnancy, between 1998 and 2008. An
exacerbation was composed of one or more medical encounters in an acute-care setting (hos-
pital-based outpatient clinic, emergency department, or during hospitalization). Data were
retrieved from medical charts and health administrative databases. We compared the use ofe Montre´al, Faculte´ de pharmacie, C.P. 6128, Succursale Centre-ville, Montre´al, Que´bec H3C 3J7,
fax: þ1 514 343 6057.
real.ca (L. Blais).
14.07.001
hts reserved.
Treatment of asthma exacerbations during and outside of pregnancy 1261systemic corticosteroids (SCSs) during and outside of pregnancy with a Cox proportional haz-
ards model.
Results: The cohort was formed of 39 women who had 40 exacerbations during and 39 exacer-
bations outside of pregnancy. Use of SCSs to treat exacerbations was less frequent (adjusted
hazard ratio: 0.51; 95% CI: 0.31e0.84) during pregnancy. Moreover, upon the first medical
encounter related to the exacerbation, SCSs, when administered, were given less frequently
to women when pregnant than when non-pregnant (83% vs. 100%). The SCS prescription was
filled at the community pharmacy 65% and 67% of the time when it was prescribed at discharge
to women when pregnant than when non-pregnant, respectively.
Conclusion: We observed a reduced and delayed use of SCSs for the treatment of asthma ex-
acerbations in women when pregnant than when non-pregnant, with similar numbers of
women in both conditions filling their SCSs prescription in pharmacies.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Asthma is one of the most common potentially serious
medical conditions encountered during pregnancy affecting
3.7e8.4% of pregnancies [1,2]. Asthma exacerbations are
common during pregnancy, with 12.6%, 25.7%, and 51.9% of
women with mild, moderate, or severe asthma experi-
encing an exacerbation, respectively [3]. Current asthma
guidelines recommend equivalent treatment of exacerba-
tions for pregnant and non-pregnant women [4,5]. The
guidelines emphasize the safety of asthma medications
compared to the risk of poorly controlled asthma for the
fetus, since uncontrolled asthma during pregnancy was
found to be associated with increased risks of perinatal
complications [4e10]. These notions were already present
in the National Asthma Education and Prevention Program
guidelines of 1997 [11]. Despite these recommendations,
two American studies reported that the percentage of
systemic-corticosteroid (SCS) use for the treatment of an
asthma exacerbation was about 20% less at the emergency
department (ED) and at discharge between pregnant and
non-pregnant women [12,13]. These studies did not eval-
uate medical visits at a hospital-based outpatient clinic, or
hospitalizations.
The main purpose of this study was to compare SCS use
for the treatment of asthma exacerbations during and
outside of pregnancy in a non-US acute-care setting,
including medical visits at a hospital-based outpatient
clinic, ED visit, and/or hospitalization. The study was un-
dertaken because the literature reports that prescribing ED
practices to treat asthma exacerbations differ between US
and non-US centers [14].
Methods
Study design
From a cohort of pregnant asthmatic women giving birth in
the province of Quebec, Canada, between 1998 and 2008
we identified women who had an asthma exacerbation
managed at the Centre hospitalier universitaire de Sher-
brooke (CHUS),da teaching hospitaldduring or in the year
preceding pregnancy [15]. The inclusion criteria for thiscohort were: (1) singleton delivery between 1998 and 2008,
(2) a medical encounter (medical visit at a hospital-based
outpatient clinic, ED visit, and/or hospitalization) for an
asthma exacerbation at the CHUS one year prior to or
during pregnancy, (3) 45 years of age or younger at the time
of delivery, (4) having at least one diagnosis of asthma
(International Classification of Diseases [ICD], ICD-9 code:
493 [except 493.2] or ICD-10 code: J45) and at least 1
prescription for an asthma medication filled in the year
before or during pregnancy, and (5) being covered by the
RAMQ drug-insurance plan for at least one year before the
exacerbation and to the end of pregnancy. If a woman
contributed several pregnancies, we kept only the two most
recent. Information on in- and outpatient care provided in
the province of Quebec was obtained from two adminis-
trative databases: the Re´gie de l’assurance-maladie du
Que´bec (RAMQ) (providing information on medication pre-
scriptions (i.e. SCSs) filled in community pharmacies,
outpatient medical visits, and ED visits) and MED-ECHO
(providing information on asthma-related hospitaliza-
tions). To determine pregnancy duration, we retrospec-
tively identified the date of the first day of the subject’s
last menstrual period and the date of delivery for each
pregnancy using gestational age at birth and offspring date
of birth.
Asthma exacerbations and hospital data collection
An asthma exacerbation was defined as one or more medical
encounters related to the condition when no more than 14
days elapsed between two adjacent visits. A medical
encounter was considered to be due to an asthma exacer-
bation when one of the following terms was found in the
medical chart: bronchospasm, asthma exacerbation, asthma
crisis, status asthmaticus, or decompensated asthma. Two
persons (MC and CR) independently assessed whether or not
eachmedical encounter was due to an asthma exacerbation.
All medical encounters were reviewed whether or not an
ICD-9 code for asthma was present. Discordant cases were
resolved by a consensus review by two pharmacists (BC and
MFB). For each medical encounter due to an asthma exac-
erbation, we collected the visit’s starting and ending dates
as well as its location (hospital-based outpatient clinic, ED,
and/or hospitalization) from the hospital electronic health
1262 B. Cossette et al.record. If a womanwas seen in different locations during the
exacerbation, a single location was attributed according to
the following hierarchy: hospitalization, ED visit, and
hospital-based outpatient visit. The exacerbation’s duration
was defined as the last day of the last medical encounter
minus the first day of the first medical encounter þ1,
including days between medical encounters. To illustrate,
for a patient seen at the ED on days 1 and 2, sent home on day
2, and then seen again at the ED on days 5 and 6, the duration
of exacerbation would be 6 days. Data on spirometry and
asthma medications taken during medical encounters and
prescribed at discharge were collected by a single individual
(MC) using a standardized electronic-data form.
Outcomes
The use of SCSs during an exacerbation or in the subsequent
14 days was the main outcome. Exposure to SCSs (predni-
sone or methylprednisolone) during a medical encounter
was defined as an active prescription of SCSs in the pa-
tient’s chart. Outpatient exposure to SCSs (prednisone) was
defined as at least one prescription filled at a community
pharmacy, from the start of the exacerbation and up to 14
days subsequent to the exacerbation. More specifically, for
the Cox regression, the outcome was defined as the time to
the first SCS exposure (medical encounter or community
pharmacy). The secondary outcomes were: (1) the use of
SCSs upon the first medical encounter for an exacerbation,
(2) the occurrence of a second medical encounter during an
exacerbation, and (3) the use of SCSs upon a second med-
ical encounter.
Potential confounding variables
Potential confounding variables measured at the time of
the exacerbation included maternal age (18e34 years,
other), maternal receipt of social assistance and the
severity of the exacerbation estimated by the maximal
daily dose of short-acting B2-agonists (SABA) administered
during a medical encounter (0e1200 mg, >1200 mg). Po-
tential confounding variables measured in the year pre-
ceding the exacerbation included diabetes (including
gestational), hypertension (including pregnancy-induced
hypertension) and asthma control measured by a vali-
dated algorithm (based on the use of SABA and SCSs and on
the occurrence of hospitalizations or ED visits for asthma)
[16]. The SABA dose used during the medical encounters
was retrieved from the medical charts; all other con-
founding variables were retrieved from the administrative
databases. A detailed description of the asthma control
algorithm is available upon request. Forced expiratory
volume in one second (FEV1) values were reported as a
descriptive variable but was not included in the multivar-
iate models because of missing values. FEV1 were shown to
be valid indicators of asthma control in pregnancy [17].
Statistical analysis
Descriptive statistics were used to compare the exacerba-
tion’s characteristics and SCS use between exacerbations
occurring during and outside pregnancy. We producedKaplaneMeier curves to illustrate crude hazard functions.
We estimated the crude and adjusted hazard ratios (HRs)
for SCS use by comparing exacerbations occurring during
and outside of pregnancy with a marginal Cox model for
clustered data (a woman could contribute more than one
exacerbation and be included in the pregnant and non-
pregnant groups) with a robust sandwich covariance esti-
mate to account for the intracluster correlation [18]. A
descriptive analysis of the proportion of SCS use upon the
first medical encounter, the need for a second medical
encounter for an ongoing exacerbation, and SCS use upon
the second medical encounter was also performed to
compare the exacerbations of women when pregnant and
when non-pregnant. Statistical analyses were performed
using SAS version 9.2 (SAS Institute, Inc., Cary, NC).
Ethics approval
We obtained approval from the Commission d’acce`s a` l’in-
formation du Que´bec (Quebec access-to-information com-
mission) prior to requesting and linking the information
from the Med-Echo and RAMQ databases to data from the
women’s charts. This study was approved by the ethics
committees of the Hoˆpital du Sacre´-Coeur de Montre´al and
the Centre hospitalier universitaire de Sherbrooke.
Results
Exacerbation’s characteristics
As shown in Fig. 1, the cohort was composed of 39 women
who had 79 exacerbations: 40 during and 39 outside of
pregnancy. Of the 40 exacerbations during pregnancy, 8,
17, and 15 occurred in the first, second, and third tri-
mesters respectively. Table 1 gives the characteristics of
the exacerbations according to whether or not they
occurred during pregnancy. The women had a mean age of
25.3 years and 60.8% were receiving social assistance at the
time of the exacerbation. The mean number of medical
encounters per exacerbation was 1.2 during and 1.1 outside
of pregnancy. Fig. 1 describes the different locations of the
medical encounters accounting for the exacerbations. The
similar forced expiratory volume in one second (FEV1)
values suggest a comparable severity of the exacerbations
between the groups, but the data were available for 21
exacerbations that occurred during and 24 that occurred
outside of pregnancy. Twenty-eight percent of the exac-
erbations were managed during hospital-based outpatient-
clinic visits with higher FEV1 values (data not shown) during
these visits compared to ED visits or hospitalizations. This
might indicate less severe exacerbations in the hospital-
based outpatient-clinic setting. The high frequency of
weekly SABA use and the number of SCS prescriptions in the
year preceding the exacerbations suggest that asthma
control was poor in both groups. The mean daily dose of ICS
was similar in both groups and could be qualified as a low
dose according to GINA guidelines [4]. long-acting b2-ago-
nists (LABA) use was greater outside of pregnancy, which
was expected for a class of medication with limited safety
data during pregnancy [15]. The pregnant group comprised
a larger proportion of women with diabetes.
Table 1 Characteristics of the exacerbations that
occurred during and outside of pregnancy.
Subjects n Exacerbations
during pregnancy
Exacerbations
outside of
pregnancy
40 39
Characteristics at the time of the exacerbation
Age, mean  SD 26.3  5.3 24.2  5.5
Receipt of social
assistance, n (%)
24 (60.0) 24 (61.5)
Location of medical encounter during the exacerbation, n
(%)
Hospital-based
outpatient clinic
11 (27.5) 1 (2.6)
Emergency room 11 (27.5) 27 (69.2)
Hospitalization 18 (45.0) 11 (28.2)
Duration of exacerbation
1 day 12 (30.0) 19 (48.7)
Median (min.emax.) 3.0 (1e36) 2.0 (1e20)
FEV1
a,% predicted  SD 59.2  19.2 55.8  15.3
Use of SABA, n (%)
0e1200 mgb 22 (55.0) 20 (51.3)
>1200 mg 18 (45.0) 19 (48.7)
Characteristics in the year preceding the exacerbation
Asthma control, n (%) 14 (35.0) 6 (15.4)
ICS non-users, n (%) 10 (25.0%) 12 (30.8%)
ICS dosec among users 231.8  215.8 257.9  157.7
Use of LABA, n (%) 11 (27.5) 16 (41.0)
SABA (doses/week), n (%)
0e3 17 (42.5) 7 (18.0)
4e10 6 (15.0) 5 (12.8)
>10 17 (42.5) 27 (69.2)
SCSs,# prescriptions,
mean  SD
2.5  3.1 2.9  3.0
Hypertensiond, n (%) 5 (12.5) 4 (10.3)
Diabetese, n (%) 8 (20.0) 2 (5.1)
FEV1, forced expiratory volume; ICS, inhaled corticosteroid;
LABA, long-acting beta-agonist; SABA, short-acting beta-
agonist; SCS, systemic corticosteroids; SD, standard deviation.
a FEV1 values were available for 21 and 24 exacerbations in
pregnant and non-pregnant women, respectively.
b Includes use of patient’s own medication without informa-
tion on the dose.
c Average dose/day in fluticasone-equivalent.
d Includes pregnancy-induced hypertension.
e Includes gestational diabetes.
Figure 1 Distribution of the exacerbations during and
outside of pregnancy. ED, emergency department; HBOC,
hospital-based outpatient clinic; HO, hospitalization. *A total
of 40 exacerbations occurred during 30 different pregnancies:
24 women had only one exacerbation, 4 women had two ex-
acerbations, and 2 women had four exacerbations. **Eight
women had exacerbations during and outside of pregnancy.
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SCS use (presented in Table 2 and Fig. 2) was lower when
the exacerbation occurred during pregnancy. There was a
greater use of SCS in the first compared to the second and
third trimesters. A secondary analysis revealed that use of
SCSs was lower in pregnant compared to non-pregnant
women regardless of the location of the medical
encounter: hospital-based outpatient clinic visits (72.7% vs.
100%), ED visits (63.6 vs. 77.8%) and hospitalizations (77.8%
vs. 90.9%). An SCS prescription was filled at the community
pharmacy (during or outside of pregnancy) in 44 of the 79
exacerbations. In all but one of these 44 exacerbations, the
prescription was filled in the seven days following the last
medical encounter for an exacerbation. A discharge SCS
prescription was documented in the patient’s chart in 47 of
79 exacerbations. Similar percentages of women, when
pregnant (13/20, 65.0%) and non-pregnant (18/27, 66.7%)
filled their SCSs prescription at a community pharmacy (up
to 14 days subsequent to the exacerbation) when a
discharge prescription for an SCS was documented in the
patient’s chart.
Multivariate model
The adjusted model presented in Table 3 revealed that SCSs
were significantly used less during pregnancy, with an
adjusted hazard ratio of 0.51 (95% CI: 0.31e0.84). This
model also revealed that women with diabetes and those
who had doses of SABA >1200 mg during a medical
encounter were significantly more likely to use SCSs. Age
and a diagnosis of hypertension in the year preceding the
exacerbation were not included in the final Cox modelbecause these factors did not meet the proportional haz-
ards assumption and because the small sample size pre-
cluded stratification according to these variables.Timing of systemic corticosteroids use
Fig. 3 shows that all women who used SCSs for an exacer-
bation that occurred outside of pregnancy received it dur-
ing the first medical encounter (including the subsequent
14 days), while the corresponding figure was 82.8% during
pregnancy. During pregnancy, when SCSs were not used
during the first medical encounter, the mean delay
Table 2 Use of systemic corticosteroids in exacerbations
that occurred during and outside of pregnancy.
Subjects, n Exacerbations
during
pregnancy
Exacerbations
outside of
pregnancy
40 39
Systemic corticosteroids
use, n (%)
29 (72.5) 32 (82.1)
During medical encounter
and filled in a
community pharmacy
12 (30.0) 17 (43.6)
During medical
encounter only
9 (22.5) 8 (20.5)
Filled in community
pharmacy only
8 (20.0) 7 (18.0)
None 11 (27.5) 7 (18.0)
Systemic corticosteroids
usea, n (%)
First trimester 7 (87.5) e
Second trimester 12 (70.6) e
Third trimester 10 (66.7) e
a Systemic corticosteroid use during a medical encounter or
filled in community pharmacy.
Table 3 Crude and adjusted hazard ratios of the use of
systemic corticosteroids during and outside of pregnancy.
Crude hazard
ratio (95% CI)
Adjusted hazard
ratio (95% CI)
Exacerbation occurring
during vs. outside
of pregnancy
0.60 (0.39e0.94) 0.44 (0.23e0.85)
Receipt of social
assistance at
the time of the
exacerbation
(yes vs. no)
0.78 (0.54e1.13) 0.74 (0.48e1.12)
Use of SABA during a medical encounter
0 mge1200 mga Reference Reference
>1200 mg 2.18 (1.52e3.14) 2.37 (1.55e3.63)
Location of medical encounter
during the exacerbation, n (%)
Hospital-based
outpatient clinic
Reference Reference
Emergency room 1.25 (0.71e2.18) 0.86 (0.46e1.63)
Hospitalization 1.48 (0.86e2.56) 0.67 (0.35e1.27)
In the year preceding the exacerbation
Uncontrolled asthma 1.26 (0.76e2.10) 1.13 (0.62e2.04)
Diabetes 1.58 (0.99e2.54) 2.26 (1.18e4.34)
a Includes use of patient’s own medication without informa-
tion on the dose recorded in the medical chart.
1264 B. Cossette et al.between the first day of the exacerbation and their use was
5.8 days. Although limited to few observations, Fig. 3 also
shows that, in pregnancy, when an SCS was not received
during the first medical encounter, a second medical
encounter was necessary in 37.5% of the exacerbations vs.
12.5% when an SCS was used.
Discussion
Main findings
We observed a reduced and delayed use of SCSs for the
treatment of asthma exacerbations in women when preg-
nant than when non-pregnant. The treatment of an exac-
erbation during pregnancy was more often done duringFigure 2 KaplaneMeier curves for the use of systemic cor-
ticosteroids during and outside of pregnancy. The longer curve
for the exacerbations of the pregnant women indicates a
longer duration of exacerbation without systemic
corticosteroids.hospitalization and in outpatient-clinic settings compared
to outside of pregnancy, when ED visits accounted for 69%
of visits.
Strengths and limitations
Our study has some limitations. Due to the retrospective
study design, we were unable to characterize the severity
of the exacerbation based on symptoms. Instead, we relied
on the maximum daily dose of SABA used during a medical
encounter and on the first recorded FEV1 value, the latter
being available for only half of the exacerbations. The
maximum daily dose of SABA cut-off was based on the
clinical experience of the investigators. It is possible that
pregnant women seek medical advice at an earlier, less
severe, stage of an exacerbation because of concern for the
baby. Other limitations are the fact that the study was
conducted at a single teaching hospital and that 61% of the
women were receiving social assistance, limiting the
generalizability of the results. The reviewers of the pa-
tient’s charts were not blinded to the presence or absence
of pregnancy or the study’s objectives. The study’s
strengths include the assessment of all medical encounters
for an exacerbation. The avoidance of recall bias by
assessing the use of pre-exacerbation medical resources
(from any institution) as well as outpatient asthma pre-
scriptions filled in any community pharmacy in the pre- and
post-exacerbation periods via data retrieved from provin-
cial databases is another strong point. Moreover, the social
desirability bias, in which physicians and women can
change their behaviors due to prospective assessment, was
avoided in this non-interventional study.
No SCSs use (first ME)
All: 29.1% (23 / 79)
Pregnant Non-pregnant
40.0% (16 / 40) 18.0% (7 / 39)
Second ME
All: 30.4% (7 / 23)
Pregnant Non-pregnant
37.5% (6 / 16) 14.3% (1 / 7)
SCSs use (second ME) 
All: 71.4% (5 / 7)
Pregnant Non-pregnant
83.3% (5 / 6) 0% (0 / 1)
SCSs use (first ME)
All: 70.9% (56 / 79)
Pregnant Non-pregnant
60.0% (24 / 40) 82.1% (32 / 39)
Second ME
All: 8.9% (5 / 56)
Pregnant Non-pregnant
12.5% (3 / 24) 6.3% (2 / 32)
SCSs use (second ME) 
All: 80.0% (4 / 5)
Pregnant Non-pregnant
66.7% (2 / 3) 100% (2 / 2)
Figure 3 Systemic corticosteroid usea during the first and subsequent medical encounters for an exacerbation. ME, medical
encounter; SCSs, systemic corticosteroids. aSystemic corticosteroid use during a medical encounter or prescription filled at a
community pharmacy up to 14 days following the medical encounter and before the subsequent medical encounter.
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In our study, SCS use during a medical encounter was 52.5%
for women when pregnant and 64.1% for women when non-
pregnant, which is comparable to what was observed in the
studies carried out by Cydulka [12] (44% during and 66%
outside of pregnancy) and McAllister [13] (51% during and
72% outside of pregnancy). Our study, which assessed ex-
acerbations managed in hospital-based outpatient clinic,
ED, and hospitalization setting differs from the work of
Cydulka [12] and McAllister [13], who assessed exacerba-
tions treated only in the ED. Two other important meth-
odological differences are that we analyzed all medical
encounters related to an exacerbation as well as multiple
exacerbations for the same woman, while other studies
were limited to a woman’s first ED visit. When SCS were not
used during the first but used in the second medical
encounter of an exacerbation, the mean delay for SCS use
was 5.8 days possibly exposing the fetus to prolonged
hypoxia which could lead to poor perinatal outcomes. We
believe that the predominant safety concern of the physi-
cians when prescribing SCSs during pregnancy is the risk of
cleft lip/palate. In the 2004 pregnancy specific guidelines
of the National Asthma Education and Prevention Program
(NAEPP), the risk for isolated cleft lip with or without cleft
palate was estimated at 0.1% in the general population and
at 0.3% for women exposed to oral corticosteroids in the
first trimester of pregnancy [9]. In the NAEPP guidelines
and in the British Thoracic Society/Scottish Intercollegiate
Guidelines Network (BTS/SIGN) Asthma Guidelines section
on pregnancy, the authors insist on the facts that the as-
sociation between SCS and cleft lip/palate has not been
constantly demonstrated and is partially based on studies
with prolonged use of SCS and at greater doses than the
usual doses to treat asthma exacerbations [5,9]. A summary
of the studies on the safety of SCSs use during pregnancy is
provided in the NAEPP 2004 guidelines [19]. In the preg-
nancy section of the GINA [4] and BTS/SIGN guidelines [5]and in the NAEPP 2004 [9] pregnancy guidelines, the au-
thors mention the importance of SCSs for the treatment of
asthma exacerbations during pregnancy without providing
any efficacy data during or outside pregnancy, the focus
being on the safety of SCSs. We assume that the recom-
mendations made in the guidelines of the efficacy of SCSs
for the treatment of exacerbations during pregnancy is
based on data outside of pregnancy. The greater proportion
of medical encounters in hospital-based outpatient clinic
and higher FEV1 values could be an indication of less severe
exacerbations in pregnant women and explain part of the
difference in SCSs use. The fact that the vast majority of
these visits were in obstetrics clinics points to the alter-
native hypothesis of a different pattern of access to care
during pregnancy. It is also possible that the higher hospi-
talization rate seen in pregnant women is done to assure a
better follow-up and is not indicative of more severe ex-
acerbations. We also found that an SCS prescription was
filled at a community pharmacy up to 14 days subsequent to
the exacerbation in 50.0% and 61.6% of the exacerbations
for women when pregnant and when non-pregnant,
respectively. Other researchers found an SCS prescription
upon discharge from the ED in 38%e41% and 64%e69% of
exacerbations of pregnant and non-pregnant women,
respectively [12,13]. The fact that 66.0% of SCSs prescribed
at discharge in our study were actually filled at a commu-
nity pharmacy allows for a better estimate of true outpa-
tient treatment following a medical encounter. With similar
percentages of prescribed SCSs being filled in community
pharmacies for women when pregnant and when non-
pregnant, we can conclude that the observed differences
in SCS use are due to prescribing differences for pregnant
and non-pregnant women. Differences in the percentages
of pregnant and non-pregnant women filling their SCSs
prescriptions could have been expected in light of the
“steroid phobia” described in a recent analysis of the
concerns of pregnant women with asthma, although it was
not observed in our study [20].
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We observed a reduced and delayed use of SCSs for the
treatment of asthma exacerbations during pregnancy as
compared to outside of pregnancy in a Canadian teaching
hospital of similar magnitude to that observed previously in
the United States [12,13]. These exacerbations occurred
among women who were using low daily doses of ICS, high
weekly doses of SABA, and more than two courses of SCSs in
the previous year, indicating suboptimal asthma manage-
ment. These observations do not reflect the recommenda-
tions of current asthma treatment guidelines, which
emphasize the importance and safety of the use of
adequate controller medications, including the use of
moderate to high doses of ICSs during pregnancy when
required, compared to the risk to the fetus due to of poorly
controlled asthma [4,9,10]. The next research step is to
assess the impact of this reduced and delayed use of SCSs
on pregnancy outcomes.Funding
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